Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Journal of Clinical Medicine · 28.11.2023 · 12 (23) · 7376
DOI: 10.3390/jcm12237376 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.11.2023. Verfasst von Eva Gonzalez Barca. Beteiligte Einrichtung: Hematology Department, Catalan Institute of Oncology-IDIBELL, University of Barcelona, 08908 Barcelona, Spain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous disease. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first-line chemo immunotherapy. In recent years, there have been several new therapeutic agents approved for the treatment of relapsed/refractory (R/R) DLBCL. These agents include anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) and monoclonal antibody therapies such as polatuzumab and tafasitamab. Nevertheless, despite the high efficacy of all these new therapies, there are still patients who do not respond or relapse, representing an unmet clinical need. This review describes new promising therapies that are in clinical development to treat R/R DLBCL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Department, Catalan Institute of Oncology-IDIBELL, University of Barcelona, 08908 Barcelona, Spain.
Zitieren
APA
Gonzalez Barca, E. (2023). Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Medicine, 12(23), 7376. https://doi.org/10.3390/jcm12237376
Vancouver
Gonzalez Barca E. Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Medicine. 2023;12(23):7376. doi:10.3390/jcm12237376
BibTeX
@article{GonzalezBarca2023,
author = {Gonzalez Barca, Eva},
title = {Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {23},
pages = {7376},
doi = {10.3390/jcm12237376}
}
EUVIMED